More than 50 cancer organizations to issue a call to action urging individuals, providers, and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
